Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yishen Huazhuo decoction, also known as Ranmaijian, is a Traditional Chinese Medicine (TCM) formulation developed by Longhua Hospital, Shanghai University of Traditional Chinese Medicine. It is specifically designed to treat atherosclerosis, particularly in patients presenting with the Kidney Deficiency and Phlegm-Turbidity syndrome according to TCM diagnostic criteria. The decoction is typically administered as an adjunctive therapy alongside standard Western medical treatments, such as statins, to inhibit the progression of carotid atherosclerosis, reduce carotid intima-media thickness, and stabilize atherosclerotic plaques. Its therapeutic mechanism is based on the TCM principles of tonifying the kidney and resolving turbidity to improve vascular health and lipid metabolism.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on yishen huazhuo decoction.